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Abstract
Indication for thermocoagulation of the Gasserian ganglion is trigeminal neuralgia resistant to pharmacologic 
treatment, which either is not effective or cannot be applied due to its side effects. In Pain Clinic of Clinic of 
Anaesthesiology and Intensive Care in Warsaw in the period from July of 2008 to June of 2011 there were 
31 thermocoagulation procedures performed in 19 patients. Age of the patients varied between 46 and 
86 years. The time of symptoms was between 2 and 30 years and pain was of intermittent character and 
its intensity in NRS was between 8 and 10 points. Thermocogulation was performed on ambulatory basis but 
in conditions of an operating room. Image of the foramen ovale was received through proper positioning 
of the patients and adjustment of the X-ray C-arm. Location of the tip of the electrode was verified by the 
C-arm, sensory and motor stimulation and injection of a dye. Time of the procedure was 60 seconds. In 18 
patients a decrease in pain lasted from 7 to 24 months was reached. For one patient data has been missing. 
In none of the patients no serious adverse effects were noted. 
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Introduction
Facial pains, due to variable pathomechanism and 
etiology, amount for a difficult diagnostic and medi-
cal management problem. They stay within interest 
boundaries of many physicians of various specializa-
tions. Rare prevalence, lack of objective diagnostic 
tests and very wide spectrum of causes and symp-
toms of the facial pain syndromes make proper 
diagnosis and introduction of effective treatment 
may be difficult [Kitt and col. 2000, Stępień, 2005]. 
Facial pain can be due to trigeminal or other cranial 
nerves damage, degeneration within musculoskel-
etal system or may have psychogenic bases [Do-
brogowski and Wordliczek 2002]. Epidemiology ma-
terial shows that trigeminal neuralgia (TN) is one of 
the most common causes of unilateral facial pain. 
Prevalence of TN is 3–5 per 100,000/year [Katusic 
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and ass.1990]. TN has been known in medicine for 
may centuries. The oldest description of pain due 
to TN comes from the 1st century AD. Its author 
was a Greek physician Aretheus [�akrzewska i Pat-
salos 1999]. First contemporary description of the 
disease originates from the second half of the 17th 
century and is written by an American physician 
John Locke. The intermittent nature of the pain 
was brought general attention by Nicolaus Andre 
in his thorough depiction of the illness published in 
1756 [Terrence i Fromm, 1993]. Theoretical basis for 
the modern pharmacotherapy was derived from, 
proclaimed in 1853 by Rousseau, hypothesis ex-
plaining the intermittent nature of the pain by ab-
normal, similar as in epilepsy, conduction of nerve 
impulses. Trousseau had even proposed a new name 
for the disorder: ‘epileptiform trigeminal neuralgia’ 
[Terrence i Fromm, 1993]. Effective pain reduction 
became possible with introduction of phenytoine. 
Carbamazepine was added to pharmacotherapy of 
TN in 1962 [Bloom 1962, �akrzewska et al.1997]. In 
1934 Dandy observed that neurovascular conflict 
might be a potential cause of TN [Dandy 1934]. The 
first surgical decompression of the neurovascular 
conflict was performed by Gardnem in 1959 and in 
1967 it had been popularized by Jannetta [Gardnem 
i Miklos 1959]. Neurovascular conflict theory had 
gained publicity and acceptance mainly owing to 
the results gathered by Jannetta [Jannetta 1967, 
Linsky et al. 1994]. Compression of the nerve by 
a vessel, usually superior cerebellar artery, accom-
panied by the damage to the myelin sheath of the 
nerve turned out to be the cause of neuralgia in 
most patients treated surgically and decompression 
of the conflict resulted in an immediate withdrawal 
of the symptoms [Jannetta 1967, Kozakiewicz i wsp. 
1998]. Nowadays, a theory combining peripheral 
and central etiopathogenesis of TN, proposed by 
Rappaport and Devor in 1994, has been gaining 
an increasing acceptance. They hypothesised that 
compression damage to the trigeminal nerve root 
causes hyperactivity of a bundle of neurons within 
trigeminal nerve, which acts as ingnition-starter 
[Rappaport i Devor 1994]. The best method of treat-
ment should be chosen individually for each patient 
and decided based on its effectiveness and ability 
to introduce a second-line treatment method in 
case of failure. There is a number of patients not 
responding to a given method of treatment or side 
effects of the therapy prevent its continuation. Very 
often, age and general clinical status of a patient 
enforces on a physician one concrete method of 
treatment. Unfortunately, all methods, even the most 
radical once, are bargained by some percentage of 
failure. It is always advised to apply treatment in 
a manner of increasing intensity and is usually started 
with pharmacotherapy, which is effective in 80% of 
patients. Invasive methods of treatment are intro-
duced in cases when pharmacotherapy had failed 
[Malec-Milewska 2005]. This means that from the be-
ginning there was no positive reaction to the drugs, 
side effects disallowed raising dosage to the effective 
level or after long-term therapy there was resistance 
to the currently used drugs [Kozakiewicz 1998]. 
Invasive methods of treatment include destructive 
procedures burdened with a big number of potential 
complications, decompression procedures involving 
microsurgical decompression of neural root from 
the neighbouring vessels and neurodestructive pro-
cedures [�akrzewska et al. 1997; Kozakiewicz 1998; 
Nurmikko et al. 2002]. Majority of the neurodestruc-
tive procedures involve the Gasserian ganglion and 
the most popular and most commonly performed 
is thermocoagulation [�akrzewska et al. 1999].
Material and methods
In our Pain Clinic at the Department of Anaes-
thesiology and Intensive Care in Warsaw in the 
period from July of 2008 to June of 2011 there 
were 31 thermocoagulation procedures performed 
in 19 patients. Age of the patients varied between 
46 and 86 years. Duration of the pain was between 
2 and 30 years and pain was of intermittent char-
acter and its intensity in NRS was weighed between 
8 and 10 points. In 5 patients, a few years from 
the beginning of the illness, a constant pain of 4–5 
points in NRS persisted. Pharmacological treatment 
could not be implemented due to side effects. Prior 
to the procedure each patient was informed about 
benefits and complications related to thermoco-
agulation of Gasser ganglion. Each patient, before 
signing a consent form, was given an opportunity 
ask any questions concerning the procedure. On the 
day of surgery a patient would report at the Pain 
Clinic accompanied by a close relative or friend. The 
procedure of thermocoagulation is performed on 
an ambulatory basis in an operating room, where it 
was started with inserting an intravenous cannula. 
Electrocardiogram, blood pressure and saturation 
were monitored throughout the procedure. The 
equipment used for the thermocoagulation included: 
Neuro-Therm RDG R/JK2C apparatus and 10-centim-
eter long electrodes Top Neuropole Needle supplied 
by EQUIP MEDIKEY B.V. (non-isolated tip length of 
5 mm). Patient was placed in a supine position with 
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the head slightly tilted backwards. Image of the fora-
men ovale was received through proper positioning 
of the patients and adjustment of the X-ray C-arm 
over the chest. The active electrode was placed in the 
neighbourhood of the Gasserian ganglion through 
the exposed foramen ovale and the reference elec-
trode was placed on the patient’s abdomen or lap. 
Following disinfection of the surgical area the area 
of the active electrode’s entrance, 2–3 cm laterally 
to the oral angle in the line joining the oral angle 
and mastoid process was infiltrated with local anaes-
thetic. The proper electrode location was confirmed 
by the C-arm, sensory stimulation the electrode 
absence of back flow of cerebrospinal fluid and/or 
blood was ensured. Damaged tissue was anaesthe-
tized with 1 ml of 2% lignocaine. Thermocoagulation 
was applied for 60 seconds with voltage of 21 mV 
and amperage of 50 mA. Current with such param-
eters generates at the tip of the active electrode 
temperature about 65 oC.
Conclusions
Eighteen out of nineteen patients had experi-
enced decrease in pain. One of our patient’s data 
regarding effectiveness of the procedure was miss-
ing. The rest of the patients continue to stay in 
contact with our clinic. There was total of 31 ther-
mocoagulation procedures performed in 19 patients. 
Ten patients had the procedure performed once, 
6 patients twice and on three patients the proce-
dure was performed three times. Time free of pain 
varied from 7 and 24 months (in case of recurrent 
pains). Eight of our patients after just one thermo-
coagulation has no pain until now and in 3 of the 
patients time free of pain exceeds 2 years. Seventeen 
patients are in remission phase for symptoms. For 
one patient we lack data, and for another one, due 
to recurrence of pain after 7 months, decided to 
undergo radical surgical treatment which resulted 
in alleviation of pain. In none of the patients w ob-
served severe side effects. The complications of the 
procedure such as transient swelling and bruising 
of the cheek occurs in 5 patients, transient loss of 
sensory function in 2 patients and transient eyelid 
drooping in 1 patient. 
Discussion
Thermocoagulation of the Gasserian ganglion 
has been performed in our clinic since July 2008, the 
time when we had in our disposition thermocoagula-
tion apparatus. Before July of 2008 in the patients re-
sistant to pharmacotherapy we performed neuroly-
sis of the spheno-palatine ganglion, the procedure 
which is now reserved for patients suffering from 
trigeminal neuralgia [Malec- Milewska, 2005]. The 
effectiveness of the thermocoagulation procedure 
in our material is high: in 18 out of 19 patients we 
managed to eliminate pain. In medical literature 
there is divergent data on the efficiency of this pro-
cedure. Pain relief in patients treated with the ther-
mocoagulaton of The Gasserian ganglion varies from 
56 to 100% the effectiveness immediately following 
the procedure reaches 98%. In 1–17% of cases there 
are early, one to a few months after the therapy, 
recurrences of ailments and 4–32% of patients recur-
rence some time after the procedure[Burchiel 1988, 
Fraioli et al. 1989; Broggi et al. 1990; Taha et al. 
1996; �akrzewska et al. 1999; Kanpolat et al. 2001; 
Dobrogowski et al. 2011]. The shortest time to the 
recurrence of the pain in our material was 7 months. 
In 8 patients after one-time procedure we still do not 
observe recurrence of pain and for 3 of them the time 
free of pain is more than 2 years. Thermocoagula-
tion of the Gasserian ganglion performed in techni-
cally proper manner is a safe method with a little 
number of sustained complications. Serious adverse 
events such as meningitis, abscess, cranial nerve palsy 
or blindness occur sparsely. Twenty five per cent of 
patients are endangered with sensory disorder due 
to the procedure, 1% anaesthetic dolorosa, 1–2% 
with corneal inflammation, and 20% corneal hypo-
aesthesia. Fairly common complications also include: 
contracture of the facial muscles, hyperaesthesia of 
the dermatome responding to the damaged nerve, 
swelling and bruising of the cheek [�awirski et al. 
1991; Terrence et al. 1993; Bergenheim i Hariz 1995; 
Kapral i Merhail 2001; Kanpolat et al. 2001]. In our 
material there were no serious adverse events ob-
served in none of the patients. There were minor 
complications reported such as transient swelling 
and bruising of the cheek in 5 patients, transient 
sensory disorder in 2 and eyelid drooping in 1.
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